Esketamine: A Paradigm Shift in TRD Treatment (Kim et al., NEJM, 2019)
Introduction: Kim and colleagues’ 2019 article in The New England Journal of Medicine reviews the groundbreaking approval of esketamine as […]
Problem
Esketamine: A Groundbreaking Antidepressant Explained (Kim et al., NEJM, 2019)
Introduction: In 2019, a team of experts published an article in The New England Journal of Medicine highlighting the significance
Esketamine: A Fast-Acting Treatment for Depression, Explained (Hough, FDA, 2019)
Introduction: In 2019, the FDA approved esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). This report by
FDA Committees Weigh the Risks and Benefits of Esketamine for TRD (2019)
Introduction: In 2019, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) evaluated
Esketamine: A New Hope for Treatment-Resistant Depression (FDA Advisory Committees, 2019)
Introduction: The FDA reviewed a new treatment called esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). TRD
Ketamine and Esketamine Trials for TRD: A Clinical Update (Duke Scholars, January 2023)
Introduction: Ketamine and esketamine are increasingly investigated for their potential in managing TRD. This systematic review examines clinical trials registered
Ketamine and Esketamine for Depression: Promising Hope for Tough Cases (Duke Scholars, January 2023)
Introduction: Ketamine and esketamine have been explored in medical research for treating treatment-resistant depression (TRD), a severe form of depression
Ketamine and Esketamine: Emerging Indications and Mechanisms, Oct 2024 Review
Introduction The study by Vekhova et al. (Oct 2024) presents a comprehensive review of ketamine and esketamine’s evolving role in
New Hope for Mental Health: Ketamine and Esketamine Research Trends, Oct 2024
Introduction A recent study by Vekhova, Namiot, Jonsson, and Schiöth (Oct 2024) explores the growing use of ketamine and esketamine
New Research on Medical Cannabis for Cancer Pain (Cochrane Review, 2023)
Introduction:A 2023 Cochrane review led by Dr. Winfried Häuser and colleagues explores how cannabis-based medicines might help adults manage cancer